what is gip glp 1 Beyond the pancreas: contrasting cardiometabolic actions of and GLP1 GLP-1 Receptor Agonists – Peripheral

Lee, S.L

doi: 10.1155/2014/917981 33 CorkS

The GLP-1 receptor agonist market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 to 2032 for the following segments: By Drug Class Semaglutide Dulaglutide Liraglutide Exenatide Other drug classes By Route of Administration Parenteral Oral By Application Type 2 diabetes mellitus Obesity Other applications By Distribution Channel Hospital pharmacies Retail pharmacies Online pharmacies The above information is provided for the following regions and countries: North America U.S

Nat Med 29(9):23582365 Butler J, Shah SJ, Petrie MC, Borlaug BA, Abildstrm SZ, Davies MJ, Hovingh GK, Kitzman DW, Mller DV, Verma S et al (2024) Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials

Impact The introduction of generic semaglutide is expected to lead to significant price reductions for these widely used GLP-1 drugs, making them more accessible to a larger patient population suffering from obesity and type 2 diabetes